The arrival of CFTR modulators as a new class of CF therapy in 2012 represented a paradigm shift in how the disease is managed [5], as these small molecules target the upstream underlying defect by improving the expression (correctors), function (potentiators), or quantity (amplifiers) of CFTR protein on the epithelium. Here, CFTR is linked to cystic fibrosis.